Fulcrum Therapeutics Q1 2023 Earnings Report $4.00 +0.04 (+1.01%) As of 04:00 PM Eastern Earnings HistoryForecast Fulcrum Therapeutics EPS ResultsActual EPS-$0.41Consensus EPS -$0.47Beat/MissBeat by +$0.06One Year Ago EPSN/AFulcrum Therapeutics Revenue ResultsActual Revenue$0.30 millionExpected Revenue$1.73 millionBeat/MissMissed by -$1.43 millionYoY Revenue GrowthN/AFulcrum Therapeutics Announcement DetailsQuarterQ1 2023Date5/15/2023TimeN/AConference Call ResourcesPress ReleaseFULC Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Fulcrum Therapeutics Earnings HeadlinesFulcrum Therapeutics rumor highlighted in Betaville alertDecember 24, 2024 | markets.businessinsider.comFulcrum Therapeutics (NASDAQ:FULC) shareholders have endured a 77% loss from investing in the stock three years agoDecember 19, 2024 | finance.yahoo.com24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast world of passive crypto income, where you set up a dependable income stream that works for you, whether you're at your computer or living your life.January 21, 2025 | Crypto Swap Profits (Ad)Fulcrum sketching out future plans for Bridge District in West SacramentoDecember 13, 2024 | bizjournals.com20 Reasons Why Employees And Leaders Make Time For One-On-One MeetingsDecember 5, 2024 | forbes.comFulcrum Therapeutics (FULC) Upgraded to Buy: Here's WhyNovember 28, 2024 | msn.comSee More Fulcrum Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fulcrum Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fulcrum Therapeutics and other key companies, straight to your email. Email Address About Fulcrum TherapeuticsFulcrum Therapeutics (NASDAQ:FULC), a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.View Fulcrum Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Abbott Laboratories (1/22/2025)Amphenol (1/22/2025)GE Vernova (1/22/2025)ICICI Bank (1/22/2025)Johnson & Johnson (1/22/2025)Kinder Morgan (1/22/2025)Procter & Gamble (1/22/2025)Progressive (1/22/2025)Travelers Companies (1/22/2025)CSX (1/23/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
